Biokin Pharma Secures Breakthrough Therapy Designation for izalontamab with BMS
CompanyDrug

Biokin Pharma Secures Breakthrough Therapy Designation for izalontamab with BMS

Siemens Healthineers Diagnostics Sale: Blackstone, CVC, KKR Explore €6 B Deal
CompanyDeals

Siemens Healthineers Diagnostics Sale: Blackstone, CVC, KKR Explore €6 B Deal

Baheal’s 24% Take‑over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033
CompanyDeals

Baheal’s 24% Take‑over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033

BMS Sells 60% Shanghai Stake to Hillhouse Capital, Shifting Focus to Growth
CompanyDeals

BMS Sells 60% Shanghai Stake to Hillhouse Capital, Shifting Focus to Growth

NMPA Releases 96th Reference Listed Drugs Catalog, Adding 42 New Generic Specifications
Policy / Regulatory

NMPA Releases 96th Reference Listed Drugs Catalog, Adding 42 New Generic Specifications

CSPC Pharmaceutical Group Submits Anbenitamab for NMPA Approval in HER2‑Positive Gastric Cancer
CompanyDrug

CSPC Pharmaceutical Group Submits Anbenitamab for NMPA Approval in HER2‑Positive Gastric Cancer

BioNTech and BMS Reveal Promising Interim Results for Pumitamig in ES‑SCLC
CompanyDrug

BioNTech and BMS Reveal Promising Interim Results for Pumitamig in ES‑SCLC

Summit Therapeutics Presents 2025 HARMONi Study Results at World Lung Cancer Conference
CompanyDrug

Summit Therapeutics Presents 2025 HARMONi Study Results at World Lung Cancer Conference

Guangzhou’s Bio‑Thera Solutions Secures $5.4 Million Milestone from Intas Pharma
Company

Guangzhou’s Bio‑Thera Solutions Secures $5.4 Million Milestone from Intas Pharma

FDA Launches Aggressive Campaign to Curb Misleading Drug Advertisements
CompanyPolicy / Regulatory

FDA Launches Aggressive Campaign to Curb Misleading Drug Advertisements

MSD scrapes £1 billion UK expansion, shifts life‑science research to the US
Company

MSD scrapes £1 billion UK expansion, shifts life‑science research to the US

FibroX Therapeutics Secures IND Approval for FibroCell in Lumbar Disc Degeneration
CompanyDrug

FibroX Therapeutics Secures IND Approval for FibroCell in Lumbar Disc Degeneration